Bioalpha Holdings which signed a procurement and distribution agreement with Shanghai Bukun Trading a subsidiary of Sinopharm Health Industry in January this year for the Sinopharm vaccine has now been found the venture not viable and has been terminated.
The termination could have come as Malaysia continues to rollout vaccination program through the public channels and also with regards to the type of vaccines that’s mostly limited to European makes.
According to announcement notice to Bursa submitted by Bioalpha, the company claimed that the termination will not impact on its financials and that the decision has been mutually accepted by both parties.
Sinopharm is a double dose vaccine developed by Beijing Institute of Biological Products and was given conditional approved by NMPA of China in January this year. Beside the Chinese, UAE and Bahrain have also procured the Sinopharm Vaccine including some doses donated to Vietnam and other nations by the Chinese Government.
As for the Malaysian government, it stopped purchasing Chinese made vaccines, after countries like Saudi and European nations questioned the data of the vaccines and their efficacy rate.
Currently, the local National Immunisation Program administers vaccines like Pfizer, Astra Zaneca and Sinovac, with additional approvals given to Johnson & Johnson and Moderna both from the US.
